Sylvia Kang is the co-founder and COO of Quanovate. She has built the US operation and is responsible for the commercialization of Quanovate product.
Sylvia is committed to bringing point-of-care technology to improve consumers’ health. At Quanovate, Sylvia and the team have created a FDA registered IoT smart home health test platform for high accuracy ovulation prediction.
Quanovate has a team of 26 employees, and a 11,000 ft2 of GMP, which meets ISO 13485. The product is clinically validated. The team has filed 14 intellectual properties. The CE Mark in Europe and CFDA registration in China are expected in the next few months. Quanovate has won many awards this year, including the 1st Place in InnovateHer by SBA in Bay Area, 1st Place in Innovation & Entrepreneurship Competition, 2nd Place in InnoSTARS, and MedTech Innovator Top 100 company. The US sales will start in early 2018, with China and Europe product launch to follow.
Sylvia has significant P&L general management experiences. She has taken business and product director roles in a Fortune 500 life science company, running a $80M global business.
Sylvia holds a MBA from Cornell University, and a MS in Biomedical Engineering from Columbia University.
Sylvia is also a Concert Pianist. She has won multiple international piano competitions in France, China, and Hong Kong.